NNC 45-0095

NC 45-0095 is a synthetic nonsteroidal selective estrogen receptor modulator (SERM) which was under development by Novo Nordisk for the treatment of postmenopausal osteoporosis but was never marketed.^{[1][2][3][4][5]} It is a partial agonist of the estrogen receptor (IC₅₀Tooltip half-maximal inhibitory concentration (for binding inhibition) = 9.5 nM; EC₅₀Tooltip half-maximal effective concentration = 13 nM) with mixed estrogenic and antiestrogenic activity, and shows full estrogenic activity in bone and uterus (E_maxTooltip maximal efficacy (relative to moxestrol, in Ishikawa endometrial cancer cell line) = 105%).^[1][4] The compound is a pyrrolo indolizine derivative.^[1][2] Its development was discontinued by 2003.^[5]

NNC 45-0095

Clinical data
Other names	NNC-450095
Drug class	Selective estrogen receptor modulator
Identifiers
IUPAC name 4-(1-ethylpyrrolo[2,1,5-cd]indolizin-2-yl)phenol
CAS Number	217318-90-6
PubChem CID	9903336
ChemSpider	8078990
UNII	IS4M82C29X
ChEMBL	ChEMBL420017
CompTox Dashboard (EPA)	DTXSID60432621
Chemical and physical data
Formula	C18H15NO
Molar mass	261.324 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCC1=C(C2=CC=C3N2C1=CC=C3)C4=CC=C(C=C4)O
InChI InChI=1S/C18H15NO/c1-2-15-16-5-3-4-13-8-11-17(19(13)16)18(15)12-6-9-14(20)10-7-12/h3-11,20H,2H2,1H3 Key:GBHFDPQPLXKNIU-UHFFFAOYSA-N

See also

• List of selective estrogen receptor modulators